Cellectar Biosciences Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CLRB Nasdaq 2834 http://cellectar.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cellectar Biosciences Inc

Cellectar Reports Financial Results for First Quarter 2022 and Provides a Corporate Update - May 10th, 2022 12:30 pm
Cellectar Biosciences Announces Positive DMC Review of Pivotal Trial of Iopofosine in Waldenstrom’s Macroglobulinemia - Apr 26th, 2022 12:00 pm
Cellectar Biosciences Announces Key Commercial Team Appointments - Apr 12th, 2022 12:30 pm
Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth? - Mar 23rd, 2022 10:35 pm
Cellectar Reports Financial Results for Year Ended December 2021 and Provides a Corporate Update - Mar 21st, 2022 12:30 pm
Cellectar to Participate at Upcoming Banking Conferences - Mar 10th, 2022 9:05 pm
Cellectar Biosciences Announces Executive Leadership Changes - Feb 23rd, 2022 1:00 pm
Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year? - Jan 17th, 2022 2:40 pm
Zacks.com featured highlights include: RentACenter, U.S. Physical Therapy, Cellectar Biosciences, Toro and Zymeworks - Jan 17th, 2022 12:40 pm
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks - Jan 14th, 2022 11:27 am
Cellectar to Participate in Fireside Chat at the H.C. Wainwright Bioconnect Conference - Jan 4th, 2022 1:30 pm
Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition - Dec 13th, 2021 1:30 pm
Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition - Dec 8th, 2021 1:30 pm
Cellectar’s Iopofosine I-131 Exhibits Signals of Efficacy in Phase I Study for Pediatric Brain and Solid Tumors - Nov 16th, 2021 1:30 pm
Cellectar Reports Financial Results for the Third Quarter 2021 and Provides a Corporate Update - Nov 8th, 2021 1:30 pm
Cellectar Appoints Laurence Reilly, M.D., LL.M Interim Chief Medical Officer - Nov 2nd, 2021 12:30 pm
Cellectar Announces Innovative Concierge Service for Patients Participating in Its Clinical Studies - Oct 25th, 2021 1:00 pm
Cellectar Biosciences (NASDAQ:CLRB) Is In A Good Position To Deliver On Growth Plans - Sep 24th, 2021 11:25 am
Cellectar Bio's Iopofosine Data Shows Favorable Safety Profile In Head & Neck Cancer - Sep 22nd, 2021 4:27 pm
Preliminary Data with Iopofosine I-131 in Combination with External Beam Radiation Suggests Safety and Tolerability in Relapsed or Refractory Head and Neck Cancer - Sep 22nd, 2021 12:30 pm